EUACCIssue #12 · 28 Jul - 3 Aug 2026
Record capital, six-year deal-count low: H1 2026 confirms European VC has permanently bifurcated around AI.
🧠The Big Picture
The Great Bifurcation
Europe's VC market delivered its strongest quarter in four years in Q2 2026, yet completed its fewest deals in six years across the full first half. These two facts are not contradictions. They are the same structural shift described from two different angles.
Tech.eu's H1 2026 analysis, published July 30, puts the numbers plainly: €44.1 billion raised across just 1,740 deals — a six-year low. AI absorbed 60.3% of all European venture deal value in H1 for the first time in a single half-year period. Seed-stage deal count is down 44%. The UK alone accounted for €18.7 billion, more than triple Germany's €6.3 billion. The five largest deals of 2026 — including Pure Data Centres' £2.3B data-centre financing and Isomorphic Labs' €1.8B drug-discovery round — are all AI infrastructure, AI software, or AI-adjacent hardware. Mega-rounds above €100M now account for more than half of all H1 deal value, up from 37% in 2025.
This is not a recovery in the traditional sense. It is a reorganisation. When one sector commands 60% of deal value, the ecosystem aligns around it — dealflow sourcing, VC fund theses, LP expectations, valuation benchmarks. Founders outside the AI, defence, and deep biotech nexus are competing for a structurally shrinking share of private capital.
The institutional response is already visible. On July 28, the EIC selected six companies under its STEP Scale Up call — including Cailabs (France, advanced laser communications), Cylib (Germany, battery recycling), and Paebbl (Netherlands, CO2-to-construction materials) — for potential equity of up to €30M each from a €300M 2026 budget. On July 30, Highland Europe closed Fund VI at €1.1 billion, with the British Business Bank anchoring at €65M, targeting Series B to pre-IPO AI, software, and fintech companies. Public instruments are building exactly where private early-stage capital is retreating. The bifurcation is not a crisis — it is the market pricing correctly. For founders who understand which layer of the stack they belong to, the opportunity is large.
📋Grant World
Thirteen Days, Three Deadlines
The densest grant window of H2 2026 opens now. Three major programmes close within 13 days of each other in early September — and one closes before the month begins.
⚠️ ERC Advanced Grants — 27 Aug 2026 · Up to €3.5M over 5 years · For established researchers with strong 10+ year post-PhD track records; scientific directors of EU-based companies are eligible · No match-funding required, fully non-dilutive
EIC Accelerator (full proposal, Batch 5) — 2 Sep 2026 · Up to €2.5M grant + up to €17.5M equity investment · Bimonthly schedule; September 2 is the fourth of six batches in 2026 · Short applications have no deadline and can be submitted anytime; the September full proposal is for founders already holding an invitation
MSCA Postdoctoral Fellowships — 9 Sep 2026 · Up to €175K per researcher for a 2-year placement · EU-based startups can host a fellow if partnered with a European Research Organisation or University · Warning: university internal submission deadlines are typically 4–6 weeks before the official cut-off — some close in early August
Eurostars 3 Call 11 — 10 Sep 2026, 14:00 CET · Up to ~€400K per project · SME-led R&D consortia across 37 participating countries · ~20% success rate; minimum two Eurostars-country partners required
EIC Pathfinder Challenges — 28 Oct 2026 · Grants up to €4M · Exploratory research at TRL 1–3; well suited to deep-tech founders building before the market exists
EIC Accelerator (Batch 6, final 2026 batch) — 4 Nov 2026
💶Who Got Funded
Serbia, Eindhoven, and the Public Co-Investment Pattern
Ominimo — Belgrade, Serbia / Budapest, Hungary · €20.1M · Series B · InsurTech · EBRD Ventures (lead)
Profitable since its second year, founded in 2024, annualised gross written premium running at €307M, and now valued at €1.4B — Serbia's first unicorn. EBRD Ventures, the venture arm of the European Bank for Reconstruction and Development, led the round — the most high-profile public-institution Series B lead of the year. Ominimo operates in Hungary, Poland, the Netherlands, and Sweden, with Belgium, Romania, Spain, Italy, France, and the US next.
Xeltis — Eindhoven, Netherlands · €20.5M · Growth · MedTech · Horizon 3 Healthcare (lead), EIC Fund, Invest-NL, EQT Life Sciences, VI Partners
Xeltis makes bioabsorbable vascular implants — an aXess hemodialysis access graft that the patient's own tissue gradually replaces. The round funds an FDA submission and EU commercial rollout. The cap table is a textbook blended structure: the EIC Fund and Invest-NL alongside private MedTech specialists.
Ahead Health — Zurich, Switzerland · €8.7M · Preventive healthtech · 3VC (lead), RTP Global
Blood panels, whole-body MRI, and AI-driven risk identification, priced as a consumer subscription. Ahead Health enters Germany and the Netherlands with this raise, expanding from its Swiss base. The round follows an initial €5.1M from RTP Global in January 2026.
Atomic One — Malaga, Spain · €5.6M · Seed · Agentic AI for e-commerce
Atomic One deploys AI agents that autonomously manage e-commerce workflows — inventory, pricing, customer interactions — targeting mid-market retailers. One of three Spanish Seed rounds above €5M in July 2026.
Beelzebub — Milan, Italy · €3M · Seed · AI cybersecurity · United Ventures (exclusive lead)
Beelzebub builds AI-native assumed-breach defence: honeypot deception tools that identify attackers already inside a network. Its natural market is every organisation covered by NIS2, which entered into force across EU member states in October 2024.
Apolownia — Paris, France · €1M · Seed · Blue carbon / coastal restoration · LITA, Bpifrance
Apolownia generates high-integrity carbon credits from mangrove restoration. Its BlueRizon project covers more than 4,000 hectares in Indonesia. Bpifrance co-invested alongside impact fund LITA, continuing the French public bank's push into nature-based solutions at the earliest stage.
This week's six rounds span six countries — Serbia, Netherlands, Switzerland, Spain, Italy, France — with none from the UK or Germany. A public institution co-invests in four of the six: EBRD, EIC Fund, Invest-NL, Bpifrance. The era of purely private European early-stage rounds is becoming the exception in strategic sectors.
📈Where EU Money Is Flowing
Three Structural Shifts
AI concentration is no longer a trend — it is the baseline. For the first time in a single half-year, AI absorbed 60.3% of all European venture deal value. This number will not revert to 2023 levels. Investors who ran diversified early-stage portfolios across 20 bets per fund are underperforming concentrated AI infrastructure plays. The LP feedback loop is working: Q2 2026 is Europe's strongest VC quarter in four years, driven by fewer, larger rounds. Founders outside AI should plan for a structurally harder private market and engage with the public instruments that explicitly target what private capital is deprioritising.
Public co-investment has become the standard architecture for EU growth-stage rounds. EBRD Ventures led Ominimo's Series B. The EIC Fund co-invested in Xeltis alongside EQT Life Sciences. The British Business Bank anchored Highland Europe's Fund VI at €65M. Bpifrance backed Apolownia at seed stage. What connects all of these is mandate: these institutions are required to deploy in sectors and geographies where private markets are thin. For founders building in biotech, climate, advanced manufacturing, or emerging EU markets, the public co-investor is not a last resort — it is a valuation floor and a market-access signal that private investors read.
VC fund formation has resumed at scale, and growth-stage is leading. Highland Europe's €1.1B Fund VI closed July 30, targeting Series B to pre-IPO. Norrsken Evolve closed at €62M, formalising a Dutch presence. Kembara's €750M DeepTech fund reached first close, targeting €1B. Together these represent several billion in new dry powder entering Europe's growth stage through 2026 and 2027. For founders at Series A and beyond, the follow-on pipeline is larger than it was 18 months ago.
💡One Move
File Your MSCA Application This Week
The MSCA Postdoctoral Fellowships deadline is September 9, 2026. Most EU startup founders either don't know the programme exists or assume it applies only to universities. It doesn't.
EU-based companies can host an MSCA Postdoctoral Fellow for a two-year placement under the European Fellowship scheme. The fellowship covers up to €175,000 per researcher — salary, social security, research costs, and travel — with no equity taken and no match-funding required. If your startup needs a PhD-level researcher in biotech, materials science, AI, quantum, or space, this is the most capital-efficient route available. The catch: your company must partner with a European Research Organisation or University, and those institutions set internal submission deadlines 4 to 6 weeks before the September 9 official cut-off. Some of those windows close in early August — this week.
The step: identify a European university department that works in your area, contact their research office now, and ask whether they can support an MSCA Postdoctoral Fellowship application. Work backwards from the university's internal deadline — not September 9. The academic contact is the bottleneck; the application is co-written with the researcher, and your company's hosting letter is the critical document. With EIC Accelerator on September 2 and Eurostars on September 10, MSCA sits in the densest grant week of the year — miss it and the next opportunity is 2027.
Get it every Monday
Free · 5 min read · Unsubscribe anytime
← All 11 issuesEUACC · Get funded. Build Europe.